DaVita (NYSE:DVA) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of DaVita (NYSE:DVA) from a hold rating to a buy rating in a report released on Saturday morning.

Other research analysts have also issued research reports about the company. Truist Financial set a $158.00 price target on DaVita in a research note on Thursday, February 5th. Barclays increased their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. UBS Group upped their price objective on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $155.80.

DaVita Trading Up 2.4%

Shares of DVA stock opened at $150.89 on Friday. The company has a market capitalization of $10.08 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.53 and a beta of 0.99. The firm has a 50-day moving average price of $120.72 and a 200 day moving average price of $125.17. DaVita has a twelve month low of $101.00 and a twelve month high of $157.12.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The business had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, research analysts predict that DaVita will post 10.76 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC increased its position in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in DaVita by 8.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 14,013 shares of the company’s stock valued at $1,991,000 after purchasing an additional 1,084 shares in the last quarter. Ethic Inc. raised its position in DaVita by 36.9% in the second quarter. Ethic Inc. now owns 3,091 shares of the company’s stock valued at $438,000 after purchasing an additional 833 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of DaVita by 4.0% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 113,503 shares of the company’s stock worth $16,169,000 after purchasing an additional 4,404 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.